Nyrada Inc. Stock

NYR

AU0000070195

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:57:34 2026-08-21 EDT			5-day change	1st Jan Change
0.7450 ^AUD	+0.68%		+6.43%	-33.48%

08:55pm	Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%	MT
07-26	Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive	MT

Last Transcript: Nyrada Inc.

Nyrada Inc. - Special Call

02-04

More transcripts

Managers and Directors: Nyrada Inc.

Manager	Title	Age	Since
James Bonnar CEO	Chief Executive Officer	-	2018-01-31
Alexandra Suchowerska CTO	Chief Tech/Sci/R&D Officer	-	-
Benjamin Evison CTO	Chief Tech/Sci/R&D Officer	-	2019-08-23

Director	Title	Age	Since
John Moore CHM	Chairman	61	2019-07-15
Marcus Frampton BRD	Director/Board Member	46	2019-05-31
James Bonnar BRD	Director/Board Member	-	2025-10-07

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NYRADA INC.	+0.68%	+6.43%	+175.93%	+2,659.26%	130M
LONZA GROUP AG	-0.15%	+3.95%	+3.14%	+24.45%	51.22B
REVOLUTION MEDICINES, INC.	-1.36%	+4.82%	+485.55%	+614.84%	45.38B
BEONE MEDICINES AG	-2.04%	+3.69%	+19.34%	+91.23%	41.97B
IQVIA HOLDINGS INC.	+2.72%	+6.02%	+33.33%	+19.66%	42.15B
CELLTRION, INC.	0.00%	-3.91%	+18.49%	+47.98%	31.95B
ASCENDIS PHARMA A/S	-1.85%	+3.48%	-	-	16.73B
MEDPACE HOLDINGS, INC.	+0.72%	+5.27%	+31.55%	+145.37%	17.1B
EUROFINS SCIENTIFIC SE	-0.80%	+2.56%	+6.24%	+34.38%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.50%	+3.62%	+82.64%	+46.53%	13.91B
Average	-0.16%	+3.34%	+95.13%	+409.30%	27.53B
Weighted average by Cap.	-0.23%	+3.18%	+103.67%	+152.11%

See all sector performances

Nyrada Inc. is an Australia-based biotechnology company. The Company is focused on the discovery and development of small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The Companyâ€™s lead candidate, Xolatryp, is a small molecule cardio protection and neuroprotection therapy. Xolatryp has demonstrated preclinical efficacy as an acute treatment following ischemic stroke, traumatic brain injury (TBI), and acute myocardial infarction (AMI). Xolatryp, is also a novel blocker targeting TRPC 3/6/7 ion channels, developed to mitigate secondary brain injury and prevent further brain cell death. The critical role of TRPC 3/6/7 channels in secondary injury has been validated in animal knockout models and through research-grade blockers. Its medical programs include Myocardial Ischemia and Arrhythmia Control, Stroke, and Traumatic Brain Injury.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-21	A$0.7450	+0.68%	336,971
26-08-20	A$0.7400	+4.23%	204,367
26-08-19	A$0.7100	-1.39%	139,652
26-08-18	A$0.7200	-2.04%	142,064
26-08-17	A$0.7350	+5.00%	135,483

Delayed Quote Australian S.E.

More quotes

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	111M 79.1M 67.73M 63.19M 57.98M 109M 7.57B 750M 292M 3.79B 297M 291M 12.56B	P/E 2024	-6.91x	P/E 2025	-9.91x
Enterprise Value	108M 77.02M 65.94M 61.53M 56.46M 106M 7.37B 730M 285M 3.69B 289M 283M 12.23B	EV / Sales 2024	1.84x	EV / Sales 2025	19.9x
Free-Float	45.65%	Yield 2024 *	-	Yield 2025	-

08:55pm	Nyrada's Xolatryp Drug Candidate Protects Cardiac Function in Preclinical Study; Shares Gain 5%	MT
07-26	Nyrada Builds Cash Balance in June Quarter With Receipt of R&D Tax Incentive	MT
07-05	Nyrada Doses First Patient in Phase 2a Trial of Heart Attack Drug Candidate	MT
06-15	Nyrada Says Phase 2a Trial of Heart Attack Drug Candidate on Track for 2027 Completion	MT
06-03	Nyrada Completes Cardioprotection Pilot Study for Lead Drug Candidate	MT
05-20	Nyrada Says 7 Million Unlisted Options Due to Expire in June; Shares Fall 3%	MT
05-19	Nyrada Says Rodent Study Shows Drug Candidate's Anti-Tumor Activity, Shares Up 14%	MT
05-19	Nyrada seeks trading halt	RE
04-21	Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage	MT
03-18	Nyrada On Track To Being Site Initiation Visits For Phase IIa Clinical Trial	MT
02-18	Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2025	CI
02-18	Nyrada Discloses Updated Capital Structure	MT
02-17	Nyrada Inc. Announces Board Changes	CI

22-07-25	Nyrada : Quarterly Activities Report and Appendix 4C	PU
22-06-05	Nyrada : Brain Injury Program Target Unveiled and Phase I Update	PU
22-04-18	Nyrada : Quarterly Activities Report & Appendix 4C	PU
22-03-01	Nyrada : Presentation to Meet the CEO Life Sciences Edition	PU
22-01-20	Nyrada : Quarterly Activities Report & Appendix 4C	PU

1 day	+0.68%
1 week	+6.43%
Current month	+16.41%
1 month	+30.70%
3 months	+30.70%
6 months	+30.70%
Current year	-33.48%

1 week	0.67	0.8
1 month	0.52	0.8
Current year	0.39	1.44
1 year	0.22	1.44
3 years	0.02	1.44
5 years	0.02	1.44
10 years	0.02	1.44

Nyrada Inc. Stock

Stocks

NYR

AU0000070195

Biotechnology & Medical Research

Valuation: Nyrada Inc.

Chart: Nyrada Inc.

Latest news : Nyrada Inc.

Last Transcript: Nyrada Inc.

Press Releases: Nyrada Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Nyrada Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/20/26	Rüdiger Weseloh	Free	Director	600,000	0.5485%
2/20/26	Christopher Cox	Free	Director	600,000	0.5485%
2/20/26	Ian Dixon	Free	Director	600,000	0.5485%

	2024	2025
Net sales	3.24M 2.31M 1.98M 1.84M 1.69M 3.18M 221M 21.87M 8.53M 111M 8.67M 8.48M 366M	2.4M 1.71M 1.46M 1.36M 1.25M 2.35M 163M 16.17M 6.3M 81.83M 6.41M 6.27M 271M
Net income	-1.39M -991K -848K -791K -726K -1.36M -94.79M -9.39M -3.66M -47.5M -3.72M -3.64M -157M	-4.85M -3.45M -2.95M -2.76M -2.53M -4.75M -330M -32.7M -12.75M -165M -12.95M -12.67M -548M
Net Debt	-4.77M -3.4M -2.91M -2.71M -2.49M -4.68M -325M -32.18M -12.55M -163M -12.75M -12.47M -539M	-2.93M -2.09M -1.79M -1.67M -1.53M -2.87M -200M -19.77M -7.71M -100M -7.83M -7.66M -331M